Notes
The study was funded by Astellas Pharma Inc.
Reference
Schultz NM, et al. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis. Advances in Therapy : 6 Sep 2018. Available from: URL: http://doi.org/10.1007/s12325-018-0774-1
Rights and permissions
About this article
Cite this article
Enzalutamide worth extra cost in advanced prostate cancer. PharmacoEcon Outcomes News 812, 16 (2018). https://doi.org/10.1007/s40274-018-5283-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5283-6